Old_Rip_Beak (Hive Bee)
05-01-03 07:09
No 430595
      Buprenorphine & Naloxone--Merck Indices Needed  Bookmark   

I need the Merck Index's entries for:

1. Buprenorpine Hydrochloride
2. Naloxone Hydrochloride

I've got two scripts for Suboxone, a buprenorphine/naloxone combo in a 4:1 ratio, respective.  I want to be the first fucker to separate, and thus divert, this newly available medication.

~~Old Rip
 
 
 
 
    Vitus_Verdegast
(Hive Bee)
05-01-03 14:55
No 430688
      the Merck Index  Bookmark   

Monograph Number:  1485
Title:  Buprenorphine
CAS Registry Number:  52485-79-7
CAS Name:  [5a,7a(S)]-17-(Cyclopropylmethyl)-a-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-a-methyl-6,14-ethenomorphinan-7-methanol
Additional Names:  21-cyclopropyl-7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine;  21-cyclopropyl-7a-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
Manufacturers' Codes:  RX-6029-M
Molecular Formula:  C29H41NO4
Molecular Weight:  467.64. 
Percent Composition:  C 74.48%, H 8.84%, N 3.00%, O 13.69%
Literature References:  Analgesic that demonstrates narcotic agonist-antagonist properties.  Prepn:  K. W. Bentley, GB 1136214; idem, US 3433791 (1968, 1969 to Reckitt & Sons).  See also:  K. W. Bentley, "The Morphine Alkaloids" in The Alkaloids vol.  13, R. F. Manske, Ed. (Academic Press, New York, 1971) pp 75-120.  NMR and stereochemistry:  B. C. Uff et al., Magn. Reson. Chem. 23, 454 (1985).  Pharmacology:  A. Cowan in Advan. Biochem. Psychopharmacol. vol. 8, M. C. Braude et al., Eds. (Raven Press, New York, 1974) pp 427-438; idem, J. Pharm. Pharmacol. 28, 177 (1976); W. R. Martin et al., J. Pharmacol. Exp. Ther. 197, 517 (1976).  Metabolism:  M. J. Rance, J. S. Shillingford, Biochem. Pharmacol. 25, 735 (1976).  Clinical study in chronic pain:  M. Kjaer et al., Brit. J. Clin. Pharmacol. 13, 487 (1982).  Clinical evaluation in treatment of opioid addiction:  P. J. Fudala et al., Clin. Pharmacol. Ther. 47, 525 (1990).  Review:  J. W. Lewis, "Ring C-Bridged Derivatives of Thebaine and Oripavine" in Advan. Biochem. Psychopharmacol. vol. 8, M. C. Braude et al., Eds. (Raven Press, New York, 1974) pp 123-137.  Review of pharmacology and therapeutic efficacy:  R. C. Heel et al., Drugs 17, 81-110 (1979).
Properties:  Crystals, mp 209.
Melting point:  mp 209

Derivative Type:  Hydrochloride
CAS Registry Number:  53152-21-9
Manufacturers' Codes:  CL-112302;  NIH-8805;  UM-952
Trademarks:  Buprenex (Reckitt & Colman);  Lepetan (Otsuka);  Subutex (Schering);  Temgesic (Reckitt & Colman)
Molecular Formula:  C29H41NO4.HCl
Molecular Weight:  504.11. 
Percent Composition:  C 69.10%, H 8.40%, N 2.78%, O 12.69%, Cl 7.03%

NOTE:  This is a controlled substance (narcotic):  21 CFR, 1308.15.
Therap-Cat:  Analgesic (narcotic).


-----------------------------------------------------------



Monograph Number:  6388
Title:  Naloxone
CAS Registry Number:  465-65-6
CAS Name:  (5a)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one
Additional Names:  17-allyl-4,5a-epoxy-3,14-dihydroxymorphinan-6-one;  (-)-N-allyl-14-hydroxynordihydromorphinone;  N-allylnoroxymorphone
Molecular Formula:  C19H21NO4
Molecular Weight:  327.37. 
Percent Composition:  C 69.71%, H 6.47%, N 4.28%, O 19.55%
Literature References:  Specific opioid antagonist.  Prepn:  GB 939287 (1963 to Sankyo); M. J. Lewenstein, J. Fishman, US 3254088 (1966); R. A. Olofson et al., Tetrahedron Letters 1977, 1567.  Clinical pharmacology and abuse potential:  D. R. Jasinski et al., J. Pharmacol. Exp. Ther. 157, 420 (1967).  Metabolism:  J. M. Fujimoto, Proc. Soc. Exp. Biol. Med. 133, 317 (1970).  Synthesis of (+)-form and stereospecific activity:  I. Iijima et al., J. Med. Chem. 21, 398 (1978).  Clinical trial in Alzheimer's disease:  B. Reisberg et al., N. Engl. J. Med. 308, 721 (1983).  Comprehensive description:  M. M. A. Hasson et al., Anal. Profiles Drug Subs. 14, 453-489 (1985).  Review of pharmacology and therapeutic uses:  L. F. McNicholas, W. R. Martin, Drugs 27, 81-93 (1984); of clinical experience in Alzheimer's disease:  C. Stowe, M. L. Gora, Ann. Pharmacother. 27, 447-448 (1993); in drug overdose:  J. M. Chamberlain, B. L. Klein, Am. J. Emerg. Med. 12, 650-660 (1994).
Properties:  Crystals from ethyl acetate, mp 184 (Lewenstein), 177-178 (Sankyo Co.).  [a]D20 -194.5 (c = 0.93 in CHCl3).  Sol in chloroform.  Practically insol in petr ether.
Melting point:  mp 184 (Lewenstein), 177-178 (Sankyo Co.)
Optical Rotation:  [a]D20 -194.5 (c = 0.93 in CHCl3)

Derivative Type:  Hydrochloride
CAS Registry Number:  357-08-4;  51481-60-8 (dihydrate)
Manufacturers' Codes:  EN-15304
Trademarks:  Nalone (Winthrop);  Narcan (DuPont Pharma);  Narcanti (DuPont Pharma)
Molecular Formula:  C19H21NO4.HCl
Molecular Weight:  363.84. 
Percent Composition:  C 62.72%, H 6.09%, N 3.85%, O 17.59%, Cl 9.74%
Properties:  Crystals from ethanol + ether, mp 200-205.  Sol in water, alcohol.  Practically insol in ether.
Melting point:  mp 200-205

Therap-Cat:  Narcotic antagonist.
Therap-Cat-Vet:  Narcotic antagonist.

http://www.ealasaid.com/fan/lorrelibrary/b-wing/bc/intro.wav